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Background:  Anthracycline is a potent chemotherapeutic agent that improves survival in cancer patients; meanwhile anthracycline-
induced cardiotoxicity is increasingly becoming a serious issue. We retrospectively evaluated the effects of anthracycline on cardiac 
function in patients with malignant lymphoma.
methods:  This analysis enrolled 249 patients, who were treated with chemotherapy that included anthracycline from April 2009 to March 
2013 at our hospital and whose cardiac function was followed up by echocardiography. We assessed the cumulative anthracycline dose, 
incidence of subsequent congestive heart failure (CHF), which was defined as heart failure requiring medical attention, and predictors of 
CHF. We categorized the patients into a CHF and non-CHF group.
results:  The proportion of CHF group is 6.0% (n=15) and that of non-CHF group is 94% (n=234). These groups showed no significant 
difference in median cumulative dose (274.6±123 vs. 277±75.8 mg/m2; P=0.904). Each median follow-up period is 33.7±14.0 months 
and 33.6±16.0 months. During the follow up, all-cause death was significantly higher in the CHF group than in the non-CHF group (46.7% 
vs. 15.0%; P=0.001). Pre-treatment BNP levels tended to be higher in the CHF group (161.5±229.2 vs. 56.4±68.5 pg/ml; P=0.06). Pre- 
and post-treatment left ventricular ejection fraction (LVEF) was significantly higher in the non-CHF group (pre-LVEF: 56.1±13.8% vs. 
69.8±8.1%; P=0.004, post-LVEF: 43.5±19% vs. 65.8±8.0%; P=<0.001), while atrial fibrillation (AF) appeared significantly more frequently in 
the CHF group (40% vs. 3.8%; P=<0.001).
conclusion:  Anthracycline-induced cardiotoxicity occurs at a lower cumulative dose than previously reported and we did not observe a 
correlation between cumulative dose and CHF. These results suggest that BNP elevation, decreased LVEF and appearance of AF, may be 
used as surrogate markers of CHF. Because the progression of malignant lymphoma certainly causes death, we have to cure the disease 
over it being careful about cardiotoxicity.
